Cheng-Kui Qu, M.D., Ph.D., a researcher at Emory University, received seed funding from Rally Foundation from 2018-2022. That early and consistent support allowed his lab to make meaningful progress toward developing new treatments for juvenile myelomonocytic leukemia (JMML), a rare and aggressive childhood blood cancer that is difficult to cure.  In 2018, Rally’s funding helped Dr. Qu and his team explore whether a clinically used antipsychotic drug called pimozide might have a therapeutic...

In 2018, Rally Foundation for Childhood Cancer Research said yes to a bold idea and an ambitious young scientist. That small but significant decision, a seed grant to Adam Durbin, M.D., Ph.D., did more than fund a project. It helped launch a career, a lab and a series of discoveries now rippling across the globe in the fight against childhood cancer.   This is what happens when early support meets extraordinary potential.   Tools That Touch the World   One of the most exciting outcomes of Dr....

In 2018, Hamid Bassiri, M.D., Ph.D., at the Children’s Hospital of Philadelphia received early funding from Rally Foundation for Childhood Cancer Research. That support came at the perfect moment. It gave his lab the chance to explore a big and hopeful idea. Could the immune system help save kids with neuroblastoma?  Dr. Bassiri and his team discovered how a treatment called dinutuximab, also known as Unituxin, helps the immune system find and destroy cancer cells. Today, this treatment is...

Emily Slotkin, M.D., at Memorial Sloan Kettering wanted to help kids and teens with a cancer called Ewing sarcoma. It's a fast-growing cancer in bones and soft tissue. Thanks to a grant from Rally Foundation for Childhood Cancer Research, she got to do research that looked deep into the DNA mistake, called EWSR1-FLI1, that causes this cancer.  She studied how this gene mistake works and tested new medicines that try to shut it down, like creating the perfect key for a lock. This early research...